91 related articles for article (PubMed ID: 22568512)
1. Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from different tissue sites.
Ahrens AK; Chaturvedi NK; Nordgren TM; Dave BJ; Joshi SS
Leuk Lymphoma; 2012 Nov; 53(11):2269-78. PubMed ID: 22568512
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
3. The Signal Transducer and Activator of Transcription 5B (STAT5B) Gene Promotes Proliferation and Drug Resistance of Human Mantle Cell Lymphoma Cells by Activating the Akt Signaling Pathway.
Zhang W; Liang X; Gong Y; Xiao C; Guo B; Yang T
Med Sci Monit; 2019 Apr; 25():2599-2608. PubMed ID: 30964854
[TBL] [Abstract][Full Text] [Related]
4. Combined administration of rituximab and on 013105 induces apoptosis in mantle cell lymphoma cells and reduces tumor burden in a mouse model of mantle cell lymphoma.
Prasad A; Shrivastava A; Papadopoulos E; Kuzontkoski PM; Reddy MV; Gillum AM; Kumar R; Reddy EP; Groopman JE
Clin Cancer Res; 2013 Jan; 19(1):85-95. PubMed ID: 23124440
[TBL] [Abstract][Full Text] [Related]
5. Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling.
Hegde GV; Nordgren TM; Munger CM; Mittal AK; Bierman PJ; Weisenburger DD; Vose JM; Sharp JG; Joshi SS
Int J Cancer; 2012 Dec; 131(12):2951-60. PubMed ID: 22511234
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
[TBL] [Abstract][Full Text] [Related]
8. Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research.
Klanova M; Soukup T; Jaksa R; Molinsky J; Lateckova L; Maswabi BC; Prukova D; Brezinova J; Michalova K; Vockova P; Hernandez-Ilizaliturri F; Kulvait V; Zivny J; Vokurka M; Necas E; Trneny M; Klener P
Lab Invest; 2014 Jul; 94(7):806-17. PubMed ID: 24862967
[TBL] [Abstract][Full Text] [Related]
9. A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib.
Chaturvedi NK; Hatch ND; Sutton GL; Kling M; Vose JM; Joshi SS
Leuk Lymphoma; 2019 May; 60(5):1214-1223. PubMed ID: 30424705
[TBL] [Abstract][Full Text] [Related]
10. Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression.
Bogner C; Dechow T; Ringshausen I; Wagner M; Oelsner M; Lutzny G; Licht T; Peschel C; Pastan I; Kreitman RJ; Decker T
Br J Haematol; 2010 Jan; 148(1):99-109. PubMed ID: 19821820
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
12. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.
Chen R; Chubb S; Cheng T; Hawtin RE; Gandhi V; Plunkett W
Cancer Res; 2010 Aug; 70(16):6587-97. PubMed ID: 20663900
[TBL] [Abstract][Full Text] [Related]
13. Gene mutations and actionable genetic lesions in mantle cell lymphoma.
Ahmed M; Zhang L; Nomie K; Lam L; Wang M
Oncotarget; 2016 Sep; 7(36):58638-58648. PubMed ID: 27449094
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.
Wang M; Han XH; Zhang L; Yang J; Qian JF; Shi YK; Kwak LW; Romaguera J; Yi Q
Leukemia; 2008 Jan; 22(1):179-85. PubMed ID: 17898787
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell-based therapy for mantle cell lymphoma.
Munger CM; Vose JM; Joshi SS
Int J Oncol; 2006 Jun; 28(6):1337-43. PubMed ID: 16685434
[TBL] [Abstract][Full Text] [Related]
16. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S
Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698
[TBL] [Abstract][Full Text] [Related]
17. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
[TBL] [Abstract][Full Text] [Related]
19. Development of a clinically relevant chemoresistant mantle cell lymphoma cell culture model.
He J; Hajj KA; Knapp CM; Whitehead KA
Exp Biol Med (Maywood); 2019 Aug; 244(11):865-872. PubMed ID: 31208205
[TBL] [Abstract][Full Text] [Related]
20. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]